Roche has reported that its cobas MTB and cobas MTB-RIF/INH tests are included in the latest World Health Organisation (WHO) policy guidelines on nucleic acid amplification tests (NAATs) for tuberculosis (TB) and drug-resistant TB detection.
The latest guidance increases the number of rapid molecular tests for national TB programmes in high-burden countries, providing multi-faceted diagnostic methods that can aid patients and communities.
The two Roche mycobacteria tests are indicated for use on the cobas 6800/8800 Systems to identify a combination of TB and drug-resistant TB infections using a single specimen obtained from the patient.
When an individual shows TB symptoms, the high-sensitive cobas MTB test is conducted. On obtaining a positive result, drug resistance is assessed with the cobas MTB-RIF/INH test.
Compared to other automated molecular platforms, the cobas 6800/8800 Systems can deliver results in less time at increased throughput and with the longest walk-away time available.
Furthermore, these systems are part of the Molecular Work Area, a completely integrated lab workflow approach that allows labs to enhance their efficacy, flexibility and scalability levels.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Roche Diagnostics CEO Thomas Schinecker said: “Roche’s diagnostic solutions detect both TB and drug-resistant TB, enabling patients to be diagnosed earlier and treated with the appropriate regimen to stop the spread of the disease.
“Roche plays a significant role in the fight against TB through our Global Access Program, which focuses on sustainable solutions that can help diagnose infections and save lives.”
WHO guidelines are a vital step to end the TB epidemic globally by boosting patient access to high-quality tests, Roche noted.
Through its phased End TB Strategy, WHO intends to lower overall TB incidence by 90% and anticipates a 95% decline in TB deaths by 2035.
Last month, Roche received Emergency Use Authorisation from the US Food and Drug Administration for the use of its cobas SARS-CoV-2 Nucleic acid test in point of care settings.